GSK Jan 2024 45.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 10:02AM EDT. Market open.
| Previous close | 0.0800 |
| Open | 0.0800 |
| Bid | 0.0000 |
| Ask | 0.2500 |
| Strike | 45.00 |
| Expiry date | 2024-01-19 |
| Day's range | 0.0800 - 0.0800 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.61k |
ZacksIncyte (INCY) Down on FDA Nod for Another Myelofibrosis Drug
Incyte (INCY) declines on potential competition for lead drug Jakafi from Ojjaara for the treatment of intermediate or high-risk myelofibrosis.
- Investing.com
FDA approves GSK's unique myelofibrosis treatment Ojjaara
The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (NYSE:GSK) novel treatment, Ojjaara (momelotinib), for adults with intermediate- or high-risk myelofibrosis and anemia. This announcement comes after a three-month delay due to the need for additional data review.
- Investing.com
FDA approves GSK's Ojjaara for treatment of myelofibrosis-related anaemia
The FDA has approved Ojjaara, a drug developed by GSK plc (LSE:GSK), for the treatment of intermediate or high-risk myelofibrosis in adults with anaemia, the pharmaceutical company announced on Monday. The approval comes following a three-month delay due to an FDA request for additional information.
© 2023 Yahoo. All rights reserved.
